AU740475B2 - The use of 1,2,4-triazolo(1,5-c)pyrimidine heterocyclic analogues for the preparation of medicaments useful for the treatment of cerebrovascular disturbances - Google Patents

The use of 1,2,4-triazolo(1,5-c)pyrimidine heterocyclic analogues for the preparation of medicaments useful for the treatment of cerebrovascular disturbances Download PDF

Info

Publication number
AU740475B2
AU740475B2 AU76546/98A AU7654698A AU740475B2 AU 740475 B2 AU740475 B2 AU 740475B2 AU 76546/98 A AU76546/98 A AU 76546/98A AU 7654698 A AU7654698 A AU 7654698A AU 740475 B2 AU740475 B2 AU 740475B2
Authority
AU
Australia
Prior art keywords
formula
compound
group
alkyl
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU76546/98A
Other languages
English (en)
Other versions
AU7654698A (en
Inventor
Marina Adami
Rosalia Bertorelli
Ennio Ongini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MSD Italia SRL
Original Assignee
Schering Plough SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Plough SpA filed Critical Schering Plough SpA
Publication of AU7654698A publication Critical patent/AU7654698A/en
Application granted granted Critical
Publication of AU740475B2 publication Critical patent/AU740475B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU76546/98A 1997-05-21 1998-05-14 The use of 1,2,4-triazolo(1,5-c)pyrimidine heterocyclic analogues for the preparation of medicaments useful for the treatment of cerebrovascular disturbances Ceased AU740475B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITMI97A001190 1997-05-21
IT97MI001190A IT1291372B1 (it) 1997-05-21 1997-05-21 Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie
PCT/EP1998/002852 WO1998052568A1 (en) 1997-05-21 1998-05-14 THE USE OF 1,2,4-TRIAZOLO[1,5-c]PYRIMIDINE HETEROCYCLIC ANALOGUES FOR THE PREPARATION OF MEDICAMENTS USEFUL FOR THE TREATMENT OF CEREBROVASCULAR DISTURBANCES

Publications (2)

Publication Number Publication Date
AU7654698A AU7654698A (en) 1998-12-11
AU740475B2 true AU740475B2 (en) 2001-11-08

Family

ID=11377184

Family Applications (1)

Application Number Title Priority Date Filing Date
AU76546/98A Ceased AU740475B2 (en) 1997-05-21 1998-05-14 The use of 1,2,4-triazolo(1,5-c)pyrimidine heterocyclic analogues for the preparation of medicaments useful for the treatment of cerebrovascular disturbances

Country Status (9)

Country Link
EP (1) EP0983068B1 (https=)
JP (1) JP2002502370A (https=)
CN (1) CN1255854A (https=)
AT (1) ATE209492T1 (https=)
AU (1) AU740475B2 (https=)
CA (1) CA2289847A1 (https=)
DE (1) DE69802679D1 (https=)
IT (1) IT1291372B1 (https=)
WO (1) WO1998052568A1 (https=)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60110219T2 (de) * 2000-05-26 2006-03-09 Schering Corp. Adenosin a2a rezeptor antagonisten
GB0100624D0 (en) * 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds VII
IL160307A0 (en) 2001-08-31 2004-07-25 Univ Rockefeller Phosphodiesterase activity and regulation of phosphodiesterase 1-b-mediated signaling in brain
US20040110826A1 (en) * 2001-09-28 2004-06-10 Noriaki Uesaka Receptor Antagonists
KR100687954B1 (ko) * 2001-10-15 2007-02-27 쉐링 코포레이션 아데노신 Ａ2ａ 수용체 길항제로서의이미다조（4,3-ｅ）-1,2,4-트리아졸로（1,5-ｃ） 피리미딘
IL161573A0 (en) 2001-11-30 2004-09-27 Schering Corp [1,2,4]-TRIAZOLE BICYCLIC ADENOSINE A2a RECEPTOR ANTAGONISTS
IL161716A0 (en) 2001-11-30 2004-09-27 Schering Corp ADENOSINE A2a RECEPTOR ANTAGONISTS
AR038366A1 (es) 2001-11-30 2005-01-12 Schering Corp Compuestos de 1,2,4-triazolo [1,5-c] pirimidinas sustituidas, antagonistas del receptor de adenosina a2a, composiciones farmaceuticas, el uso de dichos compuestos para la manufactura de un medicamento para el tratamiento de enfermedades del sistema nervioso central y un kit que comprende combinacion
EP1622912B1 (en) 2003-04-23 2009-05-27 Schering Corporation 2-alkynyl-and 2-alkenyl-pyrazolo- [4,3-e ] -1,2,4-triazolo- [1,5-c] -pyrimidine adenosine a2a receptor antagonists
ATE461932T1 (de) 2004-04-21 2010-04-15 Schering Corp Pyrazoloä4,3-eü-1,2,4-triazoloä1,5-cüpyrimidine als antagonisten des adenosin-a2a-rezeptors
AU2006255028B2 (en) 2005-06-06 2012-04-19 Intra-Cellular Therapies, Inc. Organic compounds
EP1934227B1 (en) 2005-09-19 2011-12-21 Schering Corporation 2-HETEROARYL-PYRAZOLO-[4, 3-e]-1, 2, 4-TRIAZOLO-[1,5-c]-PYRIMIDINE AS ADENOSINE A2a RECEPTOR ANTAGONISTS
PE20070521A1 (es) 2005-09-23 2007-07-13 Schering Corp 7-[2-[4-(6-FLUORO-3-METIL-1,2-BENCISOXAZOL-5-IL)-1-PIPERAZINIL]ETIL]-2-(1-PROPINIL)-7H-PIRAZOL-[4,3-E]-[1,2,4]-TRIAZOL-[1,5-C]-PIRIMIDIN-5-AMINA COMO ANTAGONISTA DEL RECEPTOR DE ADENOSINA A2a
ES2273599B1 (es) 2005-10-14 2008-06-01 Universidad De Barcelona Compuestos para el tratamiento de la fibrilacion auricular.
KR20090042227A (ko) 2006-06-06 2009-04-29 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
WO2008063505A1 (en) 2006-11-13 2008-05-29 Intra-Cellular Therapies, Inc. Organic compounds
WO2008070095A1 (en) 2006-12-05 2008-06-12 Intra-Cellular Therapies, Inc. Novel uses
US7723343B2 (en) 2007-03-30 2010-05-25 King Pharmaceuticals Research And Development, Inc. Adenosine A2A receptor antagonists
KR20120012831A (ko) 2007-12-06 2012-02-10 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
EP2240028B1 (en) 2007-12-06 2016-07-20 Intra-Cellular Therapies, Inc. Pyrazolopyrimidine-4,6-dione derivatives and their use as pharmaceutical
JP2011513417A (ja) 2008-03-04 2011-04-28 シェーリング コーポレイション アデノシンＡ２ａ受容体アンタゴニストとして使用するための１，２，４−トリアゾロ［４，３−ｃ］ピリミジン−３−オンおよびピラゾロ［４，３−ｅ］−１，２，４−トリアゾロ［４，３−ｃ］ピリミジン−３−オン化合物
WO2010009190A1 (en) * 2008-07-16 2010-01-21 King Pharmaceuticals Research And Development, Inc. Methods of treating atherosclerosis
MA32942B1 (fr) 2008-12-06 2012-01-02 Intra Cellular Therapies Inc Composes organiques
KR20110103949A (ko) 2008-12-06 2011-09-21 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
JP5778582B2 (ja) 2008-12-06 2015-09-16 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
EP2367430B1 (en) 2008-12-06 2014-08-13 Intra-Cellular Therapies, Inc. Organic compounds
BRPI0922809A2 (pt) 2008-12-06 2018-05-29 Intracellular Therapies Inc compostos orgânicos
EP2367431B1 (en) 2008-12-06 2015-08-05 Intra-Cellular Therapies, Inc. Organic compounds
WO2010098839A1 (en) 2009-02-25 2010-09-02 Intra-Cellular Therapies, Inc. Pde 1 inhibitors for ophthalmic disorders
JP2012526810A (ja) 2009-05-13 2012-11-01 イントラ−セルラー・セラピーズ・インコーポレイテッド 有機化合物
JP6166534B2 (ja) 2009-08-05 2017-07-19 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 新規調節タンパク質および阻害剤
TW201206937A (en) 2010-05-31 2012-02-16 Intra Cellular Therapies Inc Organic compounds
WO2011153136A1 (en) 2010-05-31 2011-12-08 Intra-Cellular Therapies, Inc. Organic compounds
EP2576551A4 (en) 2010-05-31 2014-04-16 Intra Cellular Therapies Inc ORGANIC CONNECTIONS
WO2011153135A1 (en) 2010-05-31 2011-12-08 Intra-Cellular Therapies, Inc. Organic compounds
JP6051210B2 (ja) 2011-06-10 2016-12-27 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
WO2014101120A1 (en) 2012-12-28 2014-07-03 Merck Sharp & Dohme Corp. Heterobicyclo-substituted-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties
US9801882B2 (en) 2013-02-17 2017-10-31 Intra-Cellular Therapies, Inc. Phosphodiesterase-1 inhibitors and their use in treatment of cardiovascular diseases
KR102240326B1 (ko) 2013-03-15 2021-04-13 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
EP2968338B1 (en) 2013-03-15 2019-01-09 Intra-Cellular Therapies, Inc. Pde1 inhibitors for use in the treatment and/or prevention of cns injuries, and pns diseases, disorders or injuries
JP6696904B2 (ja) 2014-01-08 2020-05-20 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 製剤および医薬組成物
EP3157926B1 (en) 2014-06-20 2019-05-15 Intra-Cellular Therapies, Inc. Organic compounds
US10285992B2 (en) 2014-08-07 2019-05-14 Intra-Cellular Therapies, Inc. Combinations of PDE1 inhibitors and NEP inhibitors and associated methods
US10131671B2 (en) 2014-08-07 2018-11-20 Intra-Cellular Therapies, Inc. Organic compounds
US9546175B2 (en) 2014-08-07 2017-01-17 Intra-Cellular Therapies, Inc. Organic compounds
CA2961212C (en) 2014-09-17 2024-02-06 Intra-Cellular Therapies, Inc. Compounds and methods
US10472347B2 (en) 2014-11-18 2019-11-12 Merck Sharp & Dohme Corp. Aminopyrazine compounds with A2A antagonist properties
HK1244427A1 (zh) 2014-12-06 2018-08-10 Intra-Cellular Therapies, Inc. 有机化合物
CA2969594A1 (en) 2014-12-06 2016-06-09 Intra-Cellular Therapies, Inc. Pde2 inhibiting organic compounds
EP3253390B1 (en) 2015-02-06 2022-04-13 Merck Sharp & Dohme Corp. Aminoquinazoline compounds as a2a antagonist
WO2016200717A1 (en) 2015-06-11 2016-12-15 Merck Sharp & Dohme Corp. Aminopyrazine compounds with a2a antagonist properties
WO2017008205A1 (en) 2015-07-10 2017-01-19 Merck Sharp & Dohme Corp. Substituted aminoquinazoline compounds as a2a antagonist
US10682354B2 (en) 2016-03-28 2020-06-16 Intra-Cellular Therapies, Inc. Compositions and methods
JP7134168B6 (ja) 2016-09-12 2024-02-02 イントラ－セルラー・セラピーズ・インコーポレイテッド 新規使用
US11498923B2 (en) 2017-12-13 2022-11-15 Merck Sharp & Dohme Llc Substituted imidazo[1,2-c]quinazolines as A2A antagonists
JP7401442B2 (ja) 2018-01-31 2023-12-19 イントラ－セルラー・セラピーズ・インコーポレイテッド 新規使用
EP4413980A3 (en) 2019-09-03 2024-10-30 Intra-Cellular Therapies, Inc. Novel compounds
CN111072676B (zh) * 2019-12-12 2021-07-16 广东东阳光药业有限公司 含氮稠合三环衍生物及其用途
US12364695B2 (en) 2020-06-02 2025-07-22 Intra-Cellular Therapies, Inc. Methods of treating inflammatory disease

Also Published As

Publication number Publication date
CA2289847A1 (en) 1998-11-26
DE69802679D1 (de) 2002-01-10
ITMI971190A0 (https=) 1997-05-21
EP0983068B1 (en) 2001-11-28
AU7654698A (en) 1998-12-11
IT1291372B1 (it) 1999-01-07
CN1255854A (zh) 2000-06-07
JP2002502370A (ja) 2002-01-22
ITMI971190A1 (it) 1998-11-21
WO1998052568A1 (en) 1998-11-26
EP0983068A1 (en) 2000-03-08
ATE209492T1 (de) 2001-12-15

Similar Documents

Publication Publication Date Title
AU740475B2 (en) The use of 1,2,4-triazolo(1,5-c)pyrimidine heterocyclic analogues for the preparation of medicaments useful for the treatment of cerebrovascular disturbances
JP6360025B2 (ja) 有機化合物
EP0856003B1 (en) 1,2,4-TRIAZOLO 1,5-c]PYRIMIDINE HETEROCYCLIC ANALOGUES HAVING ANTAGONISTIC ACTIVITY ON ADENOSINE A 2a? RECEPTOR
JP6038250B2 (ja) 有機化合物
JP4248239B2 (ja) プリン作用性レセプターアンタゴニストとしてのピロロ［２，３−ｄ］ピリミジンおよびそれらの使用
US20100323997A1 (en) Novel uses
US20090047243A1 (en) Combinations for the treatment of b-cell proliferative disorders
EP2708540B1 (en) Pyrimido-diazepinone compound
PL217269B1 (pl) Pochodne triazoliloimidazopirydyny i triazolilopuryny, zawierająca je kompozycja farmaceutyczna, ich zastosowanie, sposób ich otrzymywania oraz związki pośrednie wykorzystywane w tym sposobie
AU2002326146A1 (en) Derivatives of triazolyl-imidazopyridine and of the triazolylpurines useful as ligands of the adenosine A2a receptor and their use as medicaments
US20210353627A1 (en) Novel quinazoline egfr inhibitors
RS20050858A (sr) Kompozicija koja sadrži pde4 inhibitor i pde5 inhibitor
Baraldi et al. Pyrazolo-triazolo-pyrimidine derivatives as adenosine receptor antagonists: a possible template for adenosine receptor subtypes?
Phillis et al. Adenosine mediates sedative action of various centrally active drugs
CN108367016A (zh) 用于治疗异位脂肪堆积的a3腺苷受体配体
WO2010053127A1 (ja) α1GABAA受容体またはα5GABAA受容体の調整剤
WO2024092047A1 (en) Administration of pyrrolopyrimidine-based kinase inhibitors for treatment of psoriasis
KR20070008689A (ko) 아데노신 ａ１ 수용체 길항제 및 알도스테론 억제제를포함하는 병용 요법
MXPA99010735A (en) THE USE OF 1,2,4-TRIAZOLO[1,5-c]PYRIMIDINE HETEROCYCLIC ANALOGUES FOR THE PREPARATION OF MEDICAMENTS USEFUL FOR THE TREATMENT OF CEREBROVASCULAR DISTURBANCES
JP2641556B2 (ja) ５―（置換アミノ）―８―（フエニルまたは置換フエニル）―３Ｈ，６Ｈ―１，４，５ａ，８ａ―テトラアザアセナフチレン―３―オン
WO2007135387A1 (en) Inhibitor of adenylyl cyclase for treating a disorder of the circadian rhythm
KR20130087058A (ko) 피리미딜아미노벤즈아미드와 ｍｔｏｒ 키나제 억제제의 조합물
CZ204899A3 (cs) 3-Pyridylové enantiomery a jejich použití jako analgetik

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired